169 results
Page 2 of 9
8-K
cmxfga278i emp1q
22 May 23
Other Events
6:59am
8-K
EX-99.1
7ypqcqjwr9my
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
gt7jyse3hb zb31
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
xjrolgl zz8b6ecw
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-99.1
w3v0fmh5dobfmm
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
8-K
EX-10.1
01w31 f6utp5wqlof
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
k9yf6nlgg
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
vb4r8sw hay8rr9g4i
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
pv9t5dqocgiu94v
8 Nov 22
Regulation FD Disclosure
7:40am
8-K
EX-99.1
pvp3xxprih elb
25 Oct 22
Adaptimmune Enhances its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
8:10am
8-K
EX-99.1
e5b51ykubf33m0iu0
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
EX-99.1
rtrpc2f9
4 Aug 22
Adaptimmune Reports Second-Quarter Financial Results and Business Update
7:36am
8-K
EX-99.1
lyy1z9hi59
9 May 22
Adaptimmune Reports First Quarter Financial Results and Business Update
7:40am
8-K
EX-99.1
duaankvahpiz
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am